Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 1144

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1
Chunk 1144
---
    successfully expand its operations and implement a successful sales and marketing strategy to support commercialization.

Renovaro
Cube and BioSymetrics may not be able to compete effectively if they are unable to accomplish one or more of these or similar objectives.

If
Renovaro Cube or BioSymetrics cannot enter new collaborations in a timely manner and on acceptable terms, their efforts to develop and
commercialize their products could be delayed or adversely affected.

From
time to time, Renovaro Cube and BioSymetrics expect to engage in discussions with potential development and/or commercial collaborators
that may or may not lead to collaborations. However, Renovaro Cube and BioSymetrics cannot guarantee that any discussions will result
in development or commercial collaborations. Further, once news of discussions regarding possible collaborations are known in the general
public, regardless of whether the news is accurate, failure to announce a collaboration agreement, or the entity’s announcement
of a collaboration with an entity other than Renovaro Cube or BioSymetrics, could result in adverse speculation about either, their products
or technology, resulting in harm to their reputation and business. In addition, establishing collaborations is difficult and time-consuming and
may require significant financial investment. Potential collaborators may elect not to work with Renovaro Cube or BioSymetrics based on
their assessment of their financial, regulatory, or intellectual property position. Even if Renovaro Cube or BioSymetrics establishes
new collaborations, they may not result in the successful development or commercialization of their products or technology.

If
Renovaro Cube or BioSymetrics is unable to establish sales and marketing capabilities, they may not be successful in commercializing their
products.

Renovaro
Cube and BioSymetrics have only limited sales and marketing infrastructures and no experience as a company in the sale, marketing and
distribution of screening or diagnostic tests. In preparation of a commercial launch, Renovaro Cube and BioSymetrics are rapidly hiring
additional personnel in sales and marketing.

Factors that may inhibit
Renovaro Cube’s or BioSymetrics’ efforts to each commercialize any of their respective products include:

    ●
    its inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, customer service, medical affairs and other support personnel;

    ●
    the inability of sales personnel to persuade adequate numbers of customers, including healthcare systems and healthcare providers, to use its products;

    ●
    the inability to price its products at a sufficient price point to ensure an adequate and attractive level